Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Embolization in Interventional Oncology Market $55.6 Billion by 2031

The global market for embolization in interventional oncology estimated to reach $55.6 billion by 2031, growing at a CAGR of 5.1% over the forecast period driven by increasing demand for minimally invasive procedures, growing incidence of various types of cancer, and technological advances leading to the development of new and innovative therapies.

Embolization is a minimally invasive therapy to block a blood vessel. It is commonly used to stop bleeding as well as to stop blood flow to a tumor in order to shrink it or in preparation for removal. Embolization is a procedure that injects substances to try to block or reduce the blood flow to cancer cells. It is an option for some patients with tumors that cannot be removed by surgery, and where tumors are too large to be treated with ablation.

Embolization procedures are used for anti-tumor therapy for tumors in liver (HCC), kidneys (renal carcinoma, lungs or bones), etc. The bland embolization or transarterial embolization (TAE) and transarterial chemoembolization (TACE) have become established treatments for unresectable, intermediate-stage HCC around the world. The rising incidence of HCC in Western countries appears to correlate with the increasing prevalence of hepatitis C virus (HCV).

  • The bland embolization includes delivery of sub-millimeter microparticles through a catheter inserted in the groin and advanced into the liver under X-ray guidance to get access into the tumor vasculature.
  • The radioembolization technique combines embolization with radiation therapy and is sometimes known as Selective internal radiation therapy (SIRT) or trans-arterial radioembolization (TARE).
    • It includes microspheres loaded with a radioactive isotope (Yttrium-90) are injected into the blood vessels feeding a tumor and deliver a lethal dose of radiation into the vessels feeding the tumor thereby causing cell death.
  • The chemoembolization or trans-arterial chemoembolization (or TACE) combines embolization with chemotherapy. TACE includes delivery of intra-arterial chemotherapy to the liver through a catheter in combination with embolic material to produce ischemia.

Drug eluting bead chemoembolization (DEB-TACE) includes delivery of microparticles that are themselves loaded with the chemotherapy agent – doxorubicin – and allow for prolonged elution into the tumor microvessels. In Asia Pacific, TACE with a lipiodol-chemotherapeutic agent suspension and gelatin sponge (GS) particles, are being widely promoted.

  • There is a huge demand in this region for conventional TACE (cTACE). On the other hand, TACE procedures that use drug-eluting beads (a doxorubicinadsorbing type of DEB called DEBDOX, DEB-TACE), are mainly promoted in Europe and the United States.

The global embolization in interventional oncology market report estimates the market size ($million 2021 to 2031), market share, growth trends and forecast (CAGR% 2024 to 2031).

The global embolization in cancer market segmented by procedure type [bland embolization (TAE), radioembolization (TARE), transarterial chemoembolization (TACE)], number of procedures [(bland embolization, radioembolization (SIRT), transarterial chemoembolization] and geography.

  • Based on procedure type, the bland embolization or transarterial embolization (TAE) segment accounted for the largest share of the total embolization in interventional oncology market.
    • According to Cancer Research U.K., the transarterial embolization (TAE) is being performed to block the blood supply to liver cancer.
    • Hepatic embolization blocks the blood supply to the carcinoid tumors in the liver which reduced the tumor size in 60% of the patients.
      • Moreover, TAE is equally effective as TACE at a lower cost and with potentially fewer side effects due to the lack of chemotherapy.
        • Existing evidence from randomized controlled trials suggest that bland transarterial embolization (TAE) has the same efficacy with TACE.
    • TAE and TACE are increasingly used to treat unresectable primary and metastatic liver tumors with average survival rates about 78% for the TAE patients and 74% for the TACE patients.
      • Transarterial embolization is increasingly used in the management of renal angiomyolipoma.
  • The chemoembolization (TACE) technique combining intra-arterial chemotherapy with selective tumor ischemia, has been shown by randomized controlled trials to be efficacious in the palliative setting.
    • The chemoembolization and radioembolization (TARE) are at the core of the treatment of liver cancer patients who cannot receive potentially curative therapies such as transplantation, resection or percutaneous ablation.

The choice of embolization agent depends largely upon the indication such as metal coils, polyvinyl alcohol (PVA) particles, alcohol, lipiodol, and others.

  • Although being used for decades, Lipiodol (Lipiodol Ultra Fluid, Guerbet) remains important as a tumor-seeking and radio-opaque drug delivery vector in interventional oncology. There have been efforts to improve the delivery of chemotherapeutic agents to tumors.
  • Drug-eluting bead (DEB) is a relatively novel drug delivery embolization system which allows for fixed dosing and the ability to release the anticancer agents in a sustained manner.
    • Three DEBs are available, i.e., Tandem (CeloNova Biosciences Inc.), DC-Beads (BTG) and HepaSphere (BioSphere Medical, Inc.).
  • Transarterial radioembolization (TARE) technique has been developed, and proven to be efficient and safe in advanced liver cancers and those with vascular complications.
    • In recent years, transarterial radioembolization (TARE) has gained a foothold in the treatment of liver cancers.  The advantage of TARE over transarterial chemoembolization (TACE) lies in the fact that it is usually performed in a single session, i.e. during a single hospitalization, and can also be used in patients with portal vein occlusion.
      • However, due to its high costs, TARE has thus far mostly been available in developed countries.
    • Two types of radioembolization microspheres are available i.e., SIR-Spheres (Sirtex Medical) and TheraSphere (Boston Scientific/BTG).

The global embolization in oncology market is further divided by geography into into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the North America and Europe regions led the embolization in oncology market, accounting for majority share of the global market.
    • High incidence of hepatocellular carcinoma, metastatic colorectal cancer are major factors driving the market growth in the developed regions.
    • The global market is driven by factors such as growing incidence of various types of cancer; clinical benefits of embolic agents over other therapies; and technological advances leading to the development of new and innovative therapies.

The global embolization in interventional oncology market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in the global market for embolization in interventional oncology and profiled in this report include BALT Group (Blockade Medical), Braile Biomedica, Boston Scientific Corporation (BTG International), CeloNova BioSciences, Inc., Cook Group, Inc., Johnson & Johnson (Depuy Synthes), Medtronic plc (Covidien plc), Merit Medical Systems, Inc. (BioSphere Medical, Inc.), Penumbra, Inc., Siemens Healthineers AG (Varian Medical Systems, Inc.), Sirtex Medical Limited, Stryker Corporation, Surefire Medical, Inc., and Terumo Corporation (Sequent Medical, Inc.).

  • Procedure
    • Bland Embolization (TAE)
    • Radioembolization (Selective Internal Radiation Therapy/ TARE)
    • Transarterial chemoembolization (TACE)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, South Korea, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profile
    • BALT Group (Blockade Medical)
    • Braile Biomedica
    • Boston Scientific Corporation (BTG International)
    • CeloNova BioSciences, Inc.
    • Cook Group, Inc.
    • Johnson & Johnson (Depuy Synthes)
    • Medtronic plc (Covidien plc)
    • Merit Medical Systems, Inc. (BioSphere Medical, Inc.)
    • Penumbra, Inc.
    • Siemens Healthineers AG (Varian Medical Systems, Inc.)
    • Sirtex Medical Limited
    • Stryker Corporation
    • Surefire Medical, Inc.
    • Terumo Corporation (Sequent Medical, Inc.)

To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/embolization-interventional-oncology-market/

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com